A PRP clinic Scottsdale residents can visit should explain platelet-rich plasma, a shot made from blood

Years of use can leave a joint sore

Age and old injuries can change how a shoulder, knee or hip moves. Cartilage, the smooth cover on bone ends inside a joint, can wear thin. Movement may then feel stiff, rough or sore. Muscle pulls on bone through a tough cord called a tendon. That cord can ache beside the joint even when the joint isn't the cause. Gardening, stairs or a long walk may bring the soreness back.

The time and place of the ache help a doctor know what to examine.

Easier movement often helps more than bed rest

On a bad day, make the walk shorter and choose familiar exercises. Complete rest can add stiffness. Warmth may loosen a stiff joint, while cooling the area may ease swelling after use. Stop if movement brings sharp pain or the joint gives way. A cane or brace may help when one has already been fitted. Don't change medicine on your own if you take blood thinners or have heart, kidney or stomach trouble.

Walking less, moving gently and using warmth or cold are the small changes that may help.

Soreness that keeps returning is worth an exam

During an exam, a doctor checks swelling, strength, motion and the exact sore spot. Bring an old X-ray if you have one, along with a written medicine list. If the ache hasn't settled, QC Kinetix offers a consultation about non-surgical regenerative treatments, meaning choices such as PRP. Doctors call it platelet-rich plasma, or PRP. Office staff draw the blood, spin it and keep the layer where platelets collect. These small blood cells clump at a cut and help start repair. Medical providers are the people who examine the joint and give care. Ask whether a doctor will examine you and who will give the shot. The first Scottsdale talk costs nothing.

The exam may show that home care needs more time or that another choice fits.

Sources

1. The American Academy of Physical Medicine and Rehabilitation convened a technical expert panel that ran a structured literature review (2023, updated through June 2025) and a modified Delphi process, and issued five evidence-based clinical recommendations plus 11 consensus-based best practices for PRP in knee osteoarthritis. The statement is explicit that orthobiologic therapies 'remain an evolving area of practice' and that robust, dose-dependent randomized controlled trials are still needed to establish PRP's clinical effects.

   Borg-Stein J, Jayaram P, Colorado BS, et al. — AAPM&R guidance statement on platelet rich plasma for knee osteoarthritis. PM&R, 2026. DOI: 10.1002/pmrj.70144.

2. In the RESTORE trial - the largest placebo-controlled PRP trial in knee osteoarthritis - 288 adults aged 50+ with symptomatic Kellgren-Lawrence grade 2-3 medial knee OA received three weekly intra-articular injections of leukocyte-poor PRP from a commercial system or saline placebo. At 12 months the mean change in knee pain was -2.1 points with PRP versus -1.8 with saline (difference -0.4; 95% CI -0.9 to 0.2; P=.17) against a minimum clinically important difference of 1.8, and the change in medial tibial cartilage volume was -1.4% versus -1.2% (difference -0.2%; 95% CI -1.9% to 1.5%; P=.81). Twenty-nine of 31 prespecified secondary outcomes showed no significant between-group difference. The authors concluded the findings do not support use of PRP for knee OA.

   Bennell KL, Paterson KL, Metcalf BR, et al. — Effect of Intra-articular Platelet-Rich Plasma vs Placebo Injection on Pain and Medial Tibial Cartilage Volume in Patients With Knee Osteoarthritis: The RESTORE Randomized Clinical Trial. JAMA, 2021. DOI: 10.1001/jama.2021.19415.

3. The devices used to spin PRP at the point of care are cleared by FDA as clinical centrifuges, product code JQC, a Class I device under 21 CFR 862.2050 - for example the Biomet GPS Platelet Separation Kit (K030555, cleared 2003) and the Harvest SmartPrep2 / SmartPrep Platelet Concentration System (K103340, cleared 2010). That clearance covers the equipment that separates blood. It is not an FDA approval of platelet-rich plasma as a treatment for osteoarthritis, tendinopathy or any other orthopedic condition, and copy must never blur the two.

   U.S. Food and Drug Administration (Center for Devices and Radiological Health) — 510(k) Premarket Notification database and Product Classification: JQC, Centrifuges (Micro, Ultra, Refrigerated) For Clinical Use, 21 CFR 862.2050. FDA accessdata (CDRH device databases), 2003.

4. The ESSKA-ICRS consensus applied the RAND/UCLA appropriateness method to 216 clinical scenarios for intra-articular PRP in knee OA. Only 84 scenarios (38.9%) were rated appropriate, 9 (4.2%) inappropriate and 123 (56.9%) uncertain. PRP was judged appropriate in patients aged 80 or under with KL grade 0-III osteoarthritis AFTER failed conservative non-injective or injective treatment; it was NOT considered appropriate as a first treatment, nor in KL grade IV (bone-on-bone) osteoarthritis, where 91.7% and 87.5% of scenarios respectively were uncertain.

   Kon E, de Girolamo L, Laver L, et al. — Platelet-rich plasma injections for the management of knee osteoarthritis: The ESSKA-ICRS consensus. Recommendations using the RAND/UCLA appropriateness method for different clinical scenarios. Knee Surgery, Sports Traumatology, Arthroscopy, 2024. DOI: 10.1002/ksa.12320.